COMMUNIQUÉS West-GlobeNewswire

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

25/01/2024 - 22:05

Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx [...]

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

25/01/2024 - 22:05

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients [...]

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

25/01/2024 - 22:05

Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics [...]

Introducing cutting-edge features to transform the dental experience: PreVu Software unveils AI-powered enhancements for smile simulation software

25/01/2024 - 21:00

FORT LAUDERDALE, FLA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PreVu Software, a pioneer in dental technology solutions, proudly announces the launch of new, innovative technology that will continue our tradition of delivering [...]

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

25/01/2024 - 20:30

Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children [...]

Communiqué de presse : Dupixent® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois

25/01/2024 - 20:30

Dupixent ® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois Approbation fondée sur les résultats de l’essai de phase III EoE KIDS ayant [...]

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

25/01/2024 - 20:29

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which Dupixent is [...]

Grant of Restricted Stock Units and Warrants to Employees in Genmab

25/01/2024 - 20:22

Company Announcement COPENHAGEN, Denmark; January 25, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,281 restricted stock units and 5,468 warrants to employees of the Company and the [...]

Confluent Announces Significant Investment in ATI Nitinol Melt Expansion

25/01/2024 - 19:54

Confluent Becomes ATI’s Fulfillment Partner for Medical Nitinol SCOTTSDALE, Ariz., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more [...]

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

25/01/2024 - 18:45

LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’ [...]

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada

25/01/2024 - 18:09

License allows PharmAla to drive revenue and growth while remaining true to its “regulatory first” mission VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or [...]

Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium

25/01/2024 - 18:03

WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial [...]

Increase of 2023 revenue at €10.5 million

25/01/2024 - 18:00

Press release Ecully, January 25, 2024 – 6.00 p.m. 2023 revenue of €10.5 million In thousands of euros Unaudited data 2023 2022 % change Q1 revenue 2,399 1,342 +79% Q2 revenue 3,034 1,770 +71% Q3 revenue 2,077 2,249 -8 [...]

Hausse du Chiffres d'affaires annuel à 10,5 millions d'euros

25/01/2024 - 18:00

Communiqué de presse Ecully, le 25 janvier 2024 – 18h00 Chiffre d’affaires 2023 de 10,5 M€ En milliers d’euros Chiffres non audités 2023 2022 Variation 2023/2022 CA 1 er trimestre 2 399 1 342 + 79% CA 2 e trimestre 3 [...]

European Bioplastics Calls for Action to Accelerate Biopolymers Industrial Growth

25/01/2024 - 16:54

BRUSSELS, Belgium, Jan. 25, 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) released its Policy Manifesto today, calling on the European Union (EU) to develop a comprehensive Biopolymers Industrial Action Plan to [...]

European Bioplastics lance un appel à l'action pour accélérer la croissance industrielle des biopolymères

25/01/2024 - 16:54

BRUXELLES, Belgique, 25 janv. 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) a publié aujourd'hui son manifeste politique, appelant l'Union européenne (UE) à développer un plan d'action industriel complet pour les [...]

QIAGEN announces partnership with Penn State University to advance microbiome sciences

25/01/2024 - 16:00

Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide instruments and solutions for shared research and education [...]

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

25/01/2024 - 15:00

Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million [...]

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

25/01/2024 - 15:00

Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors refractory to TCR [...]